Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat ...

The trend is also visible in other FMCG companies. Zydus Wellness, the company behind brands like Complan and Glucon-D, is expanding its rural coverage, focusing on increasing penetration where brands ...

Nomura has upgraded Zydus Lifesciences Ltd. to a 'buy' from its earlier 'neutral' stance, raising the target price to Rs 1,140 from Rs 1,030, implying a potential upside of 16%. Robust earnings growth ...

Brokerage firm Nomura has upgraded shares of Zydus Lifesciences Ltd. to "buy" from its earlier rating of "hold" and also raised its price target to ₹1,140 from ₹1,030 earlier. In a note on Thursday, ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic investments in the new drug applications portfolio. It "will set the way for ...

CVS Caremark will add Zydus' Zituvio™ and combination products to its template formulary Zydus Lifesciences (including its subsidiaries/affiliates, hereafter ...

Zydus Wellness Ltd announced that its subsidiary, Zydus Wellness Products Ltd, has received a GST demand of Rs 56.33 crore with interest and penalties from the tax authority. The demand relates to ...